Clinical Trial Update: Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for tocilizumab in refractory polymyositis and dermatomyositis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Polymyositis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Chester Oddis | Conditions: Dermatomyositis, Polymyositis | Phase 2 | Status: COMPLETED | Results posted: 2020-10-30